ScholarIQanswers from OpenAlex & ORCID
John R. Wunderlich
ResearcherPublications, citations & collaboration network
John R. Wunderlich is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does John R. Wunderlich have?
ScholarIQindexed works
John R. Wunderlich has 267 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does John R. Wunderlich have?
ScholarIQcitation count
John R. Wunderlich has 33,155 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of John R. Wunderlich?
ScholarIQh-index
John R. Wunderlich has an h-index of 62 in OpenAlex.
What is the i10-index of John R. Wunderlich?
ScholarIQi10-index
John R. Wunderlich has an i10-index of 106 in OpenAlex.
What is the OpenAlex record for John R. Wunderlich?
ScholarIQopenalex
The OpenAlex for John R. Wunderlich is on the source record.
What are the most-cited papers on John R. Wunderlich?
ScholarIQmost cited works
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, James Chih‐Hsin Yang, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Richard M. Sherry, Nicholas P. Restifo, Amy M. Hubicki, Michael R. Robinson, Mark Raffeld, Paul H. Duray, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda Rogers-Freezer, Sharon Mavroukakis, Steven A. Rosenberg
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang, Richard M. Sherry, Suzanne L. Topalian, Nicholas P. Restifo, Richard E. Royal, Udai S. Kammula, D E White, Sharon Mavroukakis, Linda Rogers, Gerald Gracia, Stephanie A. Jones, David P. Mangiameli, Michelle M. Pelletier, Juan Gea‐Banacloche, Michael R. Robinson, David M. Berman, Armando Filie, Andrea Abati, Steven A. Rosenberg
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg